Skip to content
Screener

BioMarin Pharmaceuticals BMRN Operating Income

Operating Income at other companies

Sarepta Therapeutics, Inc. logo
Sarepta Therapeutics, Inc.SRPT
$13.29M-88.5%
PTC Therapeutics logo
PTC TherapeuticsPTCT
$44.96M-95.4%
Zevra Therapeutics, Inc. logo
Zevra Therapeutics, Inc.ZVRA
$16.78M+124%
Agios Pharmaceuticals logo
Agios PharmaceuticalsAGIO
-$110.55M+13.0%
Regenxbio logo
RegenxbioRGNX
$29.26M+146%
BridgeBio Pharma logo
BridgeBio PharmaBBIO
-$105.96M-1.5%

Other financials

Income statement

See full
Revenue$989.7M+19.9%
Gross profit$786.9M+16.5%
Net income$44.8M-81.4%
EPS (diluted)$0.23-81.3%

Balance sheet

See full
Cash & equivalents$874.0M-28.0%
Total debt$4.2B+598%
Total equity$6.3B+4.9%
Total assets$11.7B+57.2%

Cash flow

See full
Operating cash flow$168.1M-9.3%
CapEx$28.8M+68.5%
Free cash flow$139.3M-17.2%

Valuation

See full
Market cap$11.58B-0.6%
Enterprise value$14.89B+34.9%
P/E32.2×-34.7×
P/S3.4×-0.4×

Profitability

See full
Gross margin76.1%-3.4pp
Operating margin19.9%+7.2pp
Net margin16.8%+5.1pp
FCF margin21.7%-1.0pp

Returns & leverage

See full
Return on equity9.1%+2.8pp
Debt / equity0.7×+0.6×
Current ratio2.4×-3.2×

Where this comes from

Reported directly by BioMarin Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.

The source filing: BioMarin Pharmaceuticals’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 4:14 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001048477-26-000016
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Selling, general and administrative395,549232,279653,839438,395
Intangible asset amortization73,4924,84677,9759,693
Total operating expenses878,788548,5231,515,3561,069,775
INCOME FROM OPERATIONS110,920276,887240,560500,780
Interest income10,48018,82733,04037,840
Interest expense(63,295)(2,679)(78,253)(5,542)
Other income, net3,2794,8337,2402,879
INCOME BEFORE INCOME TAXES61,384297,868202,587535,957

Item 1. Financial Statements

FAQ

What is BioMarin Pharmaceuticals's operating income?
BioMarin Pharmaceuticals (BMRN) reported operating income of $110.92M in Q2 2026.
How has BioMarin Pharmaceuticals's operating income changed year-over-year?
BioMarin Pharmaceuticals's operating income decreased by 59.9% year-over-year, from $276.89M to $110.92M.
What is the long-term trend for BioMarin Pharmaceuticals's operating income?
Over 3 years (2021 to 2024), BioMarin Pharmaceuticals's operating income has grown at a 80.5% compound annual growth rate (CAGR), from -$82.34M to $484.21M.
What does operating income mean?
Gross profit minus all operating expenses (SG&A, R&D, D&A). Measures the profit from core business operations before interest, taxes, and non-operating items.

Ask your AI about BioMarin Pharmaceuticals's operating income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude